Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,622,564 | Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof In force · High confidence | Agensys, Inc. | In force | High confidence | ||
| US 7,595,379 | Antibodies and Related Molecules That Bind to Psca Proteins Lapsed Sep 29, 2017 on the fee record Ended Sep 29, 2017 · High confidence | Agensys, Inc. | Lapsed Sep 29, 2017 on the fee record | Ended Sep 29, 2017 | High confidence | |
| US 7,541,442 | Antibodies and Related Molecules That Bind to Psca Proteins Term ended Term ended May 28, 2024 · High confidence | Agensys, Inc. | Term ended | Term ended May 28, 2024 | High confidence | |
| US 8,278,424 | Antibodies That Bind to Psca Proteins for Diagnosis of Cancer Term ended Term ended May 28, 2024 · Medium confidence | Agensys, Inc. | Term ended | Term ended May 28, 2024 | Medium confidence | |
| US 8,853,364 | Prostate Stem Cell Antigen (PSCA) Variants and Subsequences Thereof Term ended · USPTO later recorded non-payment Nov 9, 2026 Term ended May 28, 2024 · High confidence | Agensys, Inc. | Term ended USPTO later recorded non-payment Nov 9, 2026 | Term ended May 28, 2024 | High confidence | |
| US 8,013,128 | Antibodies and Related Molecules That Bind to Psca Proteins Term ended Ended no later than Oct 11, 2024 · Medium confidence | Agensys, Inc. | Term ended | Ended no later than Oct 11, 2024 | Medium confidence | |
| US 8,206,932 | Antibodies and Related Molecules That Bind to Psca Proteins Term ended Ended no later than Apr 7, 2025 · Medium confidence | Agensys, Inc. | Term ended | Ended no later than Apr 7, 2025 | Medium confidence | |
| Application 13/631,699 | Antibodies That Bind to Psca Proteins for Diagnosis of Cancer Abandoned Abandoned Dec 17, 2014 | Agensys, Inc. | Abandoned | Abandoned Dec 17, 2014 |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Agensys, Inc..
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.